** Drugmaker Biohaven's BHVN.N shares jump 8.4% to $21.51 premarket
** BHVN announces up to $600 million investment from investment firm Oberland Capital in exchange for capped milestone and royalty payments on future global net sales of its experimental drug, troriluzole
** Troriluzole is currently in late-stage development for obsessive-compulsive disorder (OCD), pending approval from the U.S. Food and Drug Administration
** Oberland may purchase up to $600 million of BHVN's bonds, of which $250 million will be funded before April end
** Covington & Burling served as legal adviser to Biohaven while Cooley advised Oberland
** All 16 brokerages covering the stock rate "buy" or higher; median PT $60 - data compiled by LSEG
** As of last close, BHVN stock down 47% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.